Two-thirds of post-approval drug studies undone (The Salt Lake Tribune)
WASHINGTON - Drug companies sometimes are allowed to hurry medicines to market in exchange for a promise to continue studying their safety and effectiveness. Those studies haven't begun in two-thirds of cases, the government reported Friday. The Food and Drug Administration said Friday that drug companies had pledged to conduct 1,231 drug studies. But as of Sept. 30, 797 - or 65 percent -